Drug Delivery Stocks List

Recent Signals

Date Stock Signal Type
2019-10-14 BDX Fell Below 20 DMA Bearish
2019-10-14 BDX Bearish Engulfing Bearish
2019-10-14 BDX NR7 Range Contraction
2019-10-14 BDX Fell Below 50 DMA Bearish
2019-10-14 BPMX 20 DMA Resistance Bearish
2019-10-14 BPMX 50 DMA Resistance Bearish
2019-10-14 EARS New 52 Week Low Weakness
2019-10-14 EARS Volume Surge Other
2019-10-14 EARS New 52 Week Closing Low Bearish
2019-10-14 EARS Lower Bollinger Band Walk Weakness
2019-10-14 EYEG 20 DMA Support Bullish
2019-10-14 EYEG 50 DMA Support Bullish
2019-10-14 HRTX NR7 Range Contraction
2019-10-14 HRTX Stochastic Reached Oversold Weakness
2019-10-14 HRTX Narrow Range Bar Range Contraction
2019-10-14 HRTX NR7-2 Range Contraction
2019-10-14 HTGC Cup with Handle Other
2019-10-14 HTGC MACD Bullish Signal Line Cross Bullish
2019-10-14 LDL 200 DMA Support Bullish
2019-10-14 MDT NR7 Range Contraction
2019-10-14 MMM Crossed Above 20 DMA Bullish
2019-10-14 MMM Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-14 MMM 50 DMA Resistance Bearish
2019-10-14 SRDX Bullish Engulfing Bullish
2019-10-14 TLC Crossed Above 20 DMA Bullish
2019-10-14 TLC Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2019-10-14 TLC MACD Bullish Signal Line Cross Bullish
2019-10-14 TLC Upper Bollinger Band Walk Strength
2019-10-14 TLC Narrow Range Bar Range Contraction
2019-10-14 TLC NR7 Range Contraction
2019-10-14 TLC Crossed Above 50 DMA Bullish
2019-10-14 WST 20 DMA Support Bullish

Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. It may involve scientific site-targeting within the body, or it might involve facilitating systemic pharmacokinetics; in any case, it is typically concerned with both quantity and duration of drug presence. Drug delivery is often approached via a drug's chemical formulation, but it may also involve medical devices or drug-device combination products. Drug delivery is a concept heavily integrated with dosage form and route of administration, the latter sometimes even being considered part of the definition.Drug delivery technologies modify drug release profile, absorption, distribution and elimination for the benefit of improving product efficacy and safety, as well as patient convenience and compliance. Drug release is from: diffusion, degradation, swelling, and affinity-based mechanisms. Some of the common routes of administration include the enteral (gastrointestinal tract), parenteral (via injections), inhalation, transdermal, topical and oral routes. . Many medications such as peptide and protein, antibody, vaccine and gene based drugs, in general may not be delivered using these routes because they might be susceptible to enzymatic degradation or can not be absorbed into the systemic circulation efficiently due to molecular size and charge issues to be therapeutically effective. For this reason many protein and peptide drugs have to be delivered by injection or a nanoneedle array.
For example, many immunizations are based on the delivery of protein drugs and are often done by injection.
Current efforts in the area of drug delivery include the development of targeted delivery in which the drug is only active in the target area of the body (for example, in cancerous tissues), sustained release formulations in which the drug is released over a period of time in a controlled manner from a formulation, and methods to increase survival of peroral agents which must pass through the stomach's acidic environment. In order to achieve efficient targeted delivery, the designed system must avoid the host's defense mechanisms and circulate to its intended site of action. Types of sustained release formulations include liposomes, drug loaded biodegradable microspheres and drug polymer conjugates. Survival of agents as they pass through the stomach typically is an issue for agents which cannot be encased in a solid tablet; one research area has been around the utilization of lipid isolates from the acid-resistant archaea Sulfolobus islandicus, which confers on the order of 10% survival of liposome-encapsulated agents.

More about Drug Delivery